Thursday, May 07, 2026 10:06:29 AM
Since the details of the Canaccord settlement were not disclosed, we cannot know the amount for sure. But we can still think about the likely ballpark, not the exact section and seat.
If Canaccord settled, it almost certainly involved no admission of fault and no punitive award. It would most likely be a negotiated payment to exit the case, avoid continued legal expense, discovery risk, and uncertainty.
The damages framework also matters. The court narrowed the surviving loss to specific NWBO stock sales tied to alleged spoofing, roughly 40.5M shares in total.
If you assume a price impact of $0.50 to $1.00 per share across the whole narrowed share count, that implies roughly $20M to $40M total gross damages before attorney fees and before allocation among defendants.
Also, that damages number is not per defendant. It is not $20M to $40M times seven. If the total gross damages were $20M to $40M across the narrowed share count, and if responsibility were divided equally among the original 7 defendants just as a rough scale check, that would be about $2.9M to $5.7M per defendant before attorney fees and settlement discounts.
If attorneys take roughly 1/3, that would net roughly $1.9M to $3.8M to NWBO from an equal share defendant before any other costs or settlement terms.
Also, if the Canaccord settlement were large enough to materially change NWBO’s financial condition, I would expect it to show up in an 8-K or later SEC filing, and I would expect it to reduce the need for further dilution. If the company continues to finance operations through debt and equity issuances, that would not support the idea that Canaccord paid a major jackpot settlement.
If Canaccord settled, it almost certainly involved no admission of fault and no punitive award. It would most likely be a negotiated payment to exit the case, avoid continued legal expense, discovery risk, and uncertainty.
The damages framework also matters. The court narrowed the surviving loss to specific NWBO stock sales tied to alleged spoofing, roughly 40.5M shares in total.
If you assume a price impact of $0.50 to $1.00 per share across the whole narrowed share count, that implies roughly $20M to $40M total gross damages before attorney fees and before allocation among defendants.
Also, that damages number is not per defendant. It is not $20M to $40M times seven. If the total gross damages were $20M to $40M across the narrowed share count, and if responsibility were divided equally among the original 7 defendants just as a rough scale check, that would be about $2.9M to $5.7M per defendant before attorney fees and settlement discounts.
If attorneys take roughly 1/3, that would net roughly $1.9M to $3.8M to NWBO from an equal share defendant before any other costs or settlement terms.
Also, if the Canaccord settlement were large enough to materially change NWBO’s financial condition, I would expect it to show up in an 8-K or later SEC filing, and I would expect it to reduce the need for further dilution. If the company continues to finance operations through debt and equity issuances, that would not support the idea that Canaccord paid a major jackpot settlement.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
